Studies

The PCCTC’s trial portfolio represents a substantial proportion of industry-sponsored and NIH-sponsored prostate cancer trials open in the US, characterizing a substantial presence in this research space. Our studies span the entire prostate cancer disease continuum and are strategically aligned with the Consortium’s own pathway-based scientific programs and a parallel commitment to the co-development of trial endpoints and biomarkers. Patient advocacy efforts are supported by Cancer ABCs.

Featured Studies

Phase III Trial of Docetaxel versus Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer

An International Registry for Men with Advanced Prostate Cancer

Our Active Study Portfolio

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase II, Randomized, 2-Arm Study of Androgen Deprivation Therapy (ADT) Plus Apalutamide And Abiraterone Acetate (AAA) versus ADT + Abiraterone Acetate (ADT + A) in Patients with High Risk Localized, Regionally Metastatic, or Low-Volume Metastatic Non-Castrate Prostate Cancers

A Phase 2 Study of Cabazitaxel plus Carboplatin in men with metastatic castrate sensitive prostate cancer with and without DNA repair mutations (CASCARA)

A Phase II Study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with CRPC Progressing on Enzalutamide or Abiraterone

A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects with mCRPC and No Mutations in DNA Damage Repair

The MAP Trial: Phase III Study of Muscadine plus (MPX) in Men with Prostate Cancer: A Randomized, Double-Blind, Placebo-Controlled Study of the Effects of MPX Capsules on Rising Prostate-Specific Antigen Levels in Alanine/Alanine SOD2 Genotype Men Following Initial Therapy for Prostate Cancer

A Phase 0 Study to Assess the Safety and Biodistribution of a Novel Radiolabeled Antibody Targeting Human Kallikrein-2 (hk2) in Subjects with mCRPC

Single Arm Phase II Study of Abiraterone + Atezolizumab + Lupron and Stereotactic Body Radiotherapy to the Prostate in Men with Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

A Phase I Dose Escalation and Expanded Cohort Study of P PSMA 101 in Subjects with mCRPC

Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

PROMISE: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

A Phase 1/2 Feasibility, Safety, And Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects with Previously Treated Advanced Solid Tumors

A Phase 1B Multiple Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration Resistant Prostate Cancer

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer

2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers

careers.mskcc.org

Committed to world-class science!

Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.

Learn More

Studies

Featured Studies

Our Active Study Portfolio

Recent News +++

Genetic Testing for Prostate Cancer: Considerations for Practice Virtual Genetics Board

Lantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer

Genetic Testing for Prostate Cancer: Considerations for Practice Virtual Genetics Board

The PCCTC Seeks Director, Clinical Data Management & Informatics

PCCTC trial is first to use standard Ra-223 doses, contemporary pain endpoints and PRO collection tools

First-of-its-Kind Study Looks at Link Between Genes and Prostate Cancer

Follow Us

2018-23944 Clinical Data Manager, Prostate Cancer Clinical Trials Consortium (PCCTC) | Memorial Sloan Kettering Cancer Center Careers

careers.mskcc.org

Committed to world-class science!

Studies

News